Manel Kraiem

Company: SKYMAB Biotherapeutics

Job title: Chief Development Officer

Seminars:

Next-Generation ADCs for GPCR-Expressing Tumors: Unlocking New Therapeutic Opportunities 5:00 pm

GPCRs as Emerging Targets: Understanding the role of GPCRs in oncogenic signaling and tumor progression Tumor-Specific GPCR Targeting: Designing ADCs with enhanced selectivity for tumorassociated GPCR isoforms Combination Strategies: Exploring synergistic effects of SKM-104 ADC with checkpoint inhibitors, chemotherapy, or radiotherapyRead more

day: Conference Day One

Fireside Chat: Examining the Future Possibilities of Modalities for GPCRTargeted Drugs to Become More Effective & Feasible 4:30 pm

Can we develop orally available peptides? How do you make a peptidic starting point into a small molecule? What are the different modalities that can be employed to target different GPCRs?Read more

day: Conference Day One